



July 21, 2016

BioCryst to Announce Second Quarter 2016 Financial Results August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2016 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (NASDAQ:BCRX) today announced that its second quarter 2016 financial results will be released on Thursday, August 4, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by [Jon P. Stonehouse](#), President and Chief Executive Officer, [Thomas R. Staab, II](#), Senior Vice President and Chief Financial Officer and [Dr. William P. Sheridan](#), Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [avoralstat](#), BCX7353 and other second generation compounds; and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910

 [Primary Logo](#)

Source: Biocryst Pharmaceuticals

News Provided by Acquire Media